GlassScriptPhysician profile
Kathleen M Benson
NPI 1235207309
$6,188.76
in general payments reported to CMS, 2019-2025
39 companies · $968 in 2025
The $968 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,418 · 2020: $492 · 2021: $441 · 2022: $591 · 2023: $472 · 2024: $808 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $893.79 | 2019-2025 | |
| Medtronic Vascular, INC. | $646.29 | 2019 | |
| Pfizer INC. | $499.14 | 2019-2025 | |
| Amgen INC. | $485.32 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $463.32 | 2019-2025 | Lifevest |
| Abiomed | $462.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $396.53 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $357.09 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $326.71 | 2019-2023 | Xarelto |
| Abbott Laboratories | $243.93 | 2019-2020 | |
| Philips North America LLC | $140.85 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $137.77 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $105.94 | 2021-2024 | Ozempic, Rybelsus |
| Ucb, INC. | $104.84 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $102.20 | 2024 | Arcalyst |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.